22Dec
Cadent Therapeutics Acquired by Novartis for Up to $770 Million
Cadent Therapeutics, a Cambridge, Massachusetts-based, privately held clinical stage biopharmaceutical company focused on the development of therapies for the treatment of cognitive, mood, and movement disorders, announced on December 17, 2020, that Novartis will acquire all of the outstanding capital stock of Cadent Therapeutics....
By:
Rothwell, Figg, Ernst & Manbeck, P.C.
Related
The European Commission is expected to issue a White Paper on an Instrument on Foreign Subsidies on ...
Read More >
It’s hard to keep up with all the recent changes to labor and employment law. While the law always ...
Read More >
The Federal Trade Commission (FTC) announced yesterday that Canon Inc. and Toshiba Corporation agree...
Read More >
UPDATED February 3, 2020. As we stated in our January 27th Alert, employers must continue monitoring...
Read More >
On August 12, 2019, Judge Haywood S. Gilliam, Jr. of the United States District Court for the Northe...
Read More >
This newsletter is our take on the antitrust developments we think are most interesting to your busi...
Read More >